Tilray Launches Medical Cannabis Products In Malta
Tilray Brands, Inc. (NASDAQ: TLRY) (TSX: TLRY) confirmed on Thursday that its medical cannabis division, Tilray Medical, has completed its first medical cannabis sale in Malta. The company EU-GMP medical cannabis products are now available in pharmacies across Maltaproviding patients with safe and reliable access to high quality medical cannabis.
Denise Faltischek, Tilray’s chief strategy officer and head of international business stated, “As demand for cannabis continues to grow across Europe, we are incredibly proud to partner with established distribution partners. and reliable to provide new markets with high quality medical cannabis that patients can rely on. on. “
In Malta, patients can obtain prescriptions for medical cannabis and a medical cannabis card through family doctors. Medical cannabis papers are issued by the Superintendent of Public Health of Malta.
Tilray Medical’s portfolio of medical cannabis brands includes Tilray, Aphria, Broken Coast, u Symbios. Tilray grew from one of the first companies to become an approved licensed producer of medical cannabis in Canada for the construction of the first GMP-certified cannabis production facilities in Europe, first in Portugal and later in Germany. Today, Tilray Medical is one of the largest suppliers of medical cannabis brands to patients, physicians, hospitals, pharmacies, researchers, and governments. in 20 countries and about five continents.
Price Action
Tilray shares were trading 0.42% lower at $ 7.17 per share during the pre-market session on Thursday.